[
  {
    "ts": null,
    "headline": "AbbVie For Healthy Dividend Growth",
    "summary": "AbbVie combines strong earnings, rising dividends, and growth from Skyrizi and Rinvoq, making it a top dividend pick. Read why ABBV stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=7c660737d9e119b19951c43ee9d6fe728274ef93d8d4956dfdd339ce01f2c0b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758956453,
      "headline": "AbbVie For Healthy Dividend Growth",
      "id": 136900538,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "AbbVie combines strong earnings, rising dividends, and growth from Skyrizi and Rinvoq, making it a top dividend pick. Read why ABBV stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=7c660737d9e119b19951c43ee9d6fe728274ef93d8d4956dfdd339ce01f2c0b5"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of […]",
    "url": "https://finnhub.io/api/news?id=f8b6ead468b9b39b0c53c3f2914a5c9fdb959ff966a5026b7aa43e46dac0c0e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758949149,
      "headline": "Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum",
      "id": 136904131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of […]",
      "url": "https://finnhub.io/api/news?id=f8b6ead468b9b39b0c53c3f2914a5c9fdb959ff966a5026b7aa43e46dac0c0e2"
    }
  }
]